Founded in 2004, BMT Diagnostics is an Israeli company with a business focus on providing rapid diagnostic solutions to the point-of-care (POC) and for self-testing.
BMT Diagnostics was the first company to introduce rapid tests for Strep A diagnosis to Israeli pharmacies, allowing patients to purchase these tests over-the-counter (OTC) prior to visiting their primary care physician. This strategy aimed at improving the process of patient`s screening at the physician`s office, thereby reducing antibiotics abuse by preventing their administration to patients tested negative for Strep A. An additional goal for this strategy was to shift Strep A screening from centralized labs to point-of-care, improving HMO service at times the centralized lab was inoperative (e.g., weekends) or overloaded.
In recent years, BMT has captured an additional market segment by selling its tests directly to leading HMOs who distribute them internally in their clinics. Of the estimated two million Strep A tests performed annually in Israel, around 500,000 are RDT, thereby validating our business model that is based on patients assuming responsibility for their own health first, followed by ENT and family physicians adoption and acceptance of Strep A RDT as a first-line diagnostic standard.
BMT develops, manufactures, distributes and sells a range of rapid diagnostic tests (RDT) in the following disease and healthcare areas:
Early markers of disease
Urinalysis and urinary tract infection (UTI)
Drugs of abuse
Bio Marketing TLab On Timewww.bio-marketing-t.com©All rights reserved
Technological advantage, Customer oriented solutions, Patented Technology, Business opportunities